Skip to main content

Table 2 IHC expression of EGFR mutation antibodies in human NSCLC cell lines and in NSCLC tumor tissues

From: Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer

EGFR mutation status EGFR (D38B1) Ab (+) EGFR E746-A750 deletion-specific (6B6) Ab (+) EGFR L858R mutant-specific (43B2) Ab (+)
H460 and A549 (WT) 2/2 (100%) 0/2 (0%) 0/2 (0%)
H1650 and PC9 (DEL 19) 2/2 (100%) 2/2 (100%) 0/2 (0%)
H1975 (L858R + T790M) 1/1 (100%) 0/1 (0%) 1/1 (100%)
Tumor Tissue (WT; N = 22) 8/22 (36%) 0/22 (0%) 0/22(0%)
Tumor Tissue (DEL 19;N = 29) 28/29 (97%) 20/29 (69%) 0/29 (0%)
Tumor Tissue (MUT 21;N = 27) 26/27 (96%) 0/27 (0%) 25/27 (93%)
  1. Abbreviations: WT: wild-type. DEL 19: Exon 19 deletion; MUT 21: Exon 21 mutation.